316 related articles for article (PubMed ID: 33740926)
21. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
[TBL] [Abstract][Full Text] [Related]
22. Avapritinib (Ayvakit) for GIST.
Med Lett Drugs Ther; 2021 Feb; 63(1617):23-24. PubMed ID: 33647006
[No Abstract] [Full Text] [Related]
23. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P;
Clin Cancer Res; 2012 Aug; 18(16):4458-64. PubMed ID: 22718859
[TBL] [Abstract][Full Text] [Related]
24. Avapritinib for metastatic or unresectable gastrointestinal stromal tumors.
Alzofon N; Jimeno A
Drugs Today (Barc); 2020 Sep; 56(9):561-571. PubMed ID: 33025950
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.
Huang W; Yuan W; Ren L; Liang H; Du X; Sun X; Fang Y; Gao X; Fu M; Sun Y; Shen K; Hou Y
Pathol Res Pract; 2022 Nov; 239():154138. PubMed ID: 36183438
[TBL] [Abstract][Full Text] [Related]
26. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
[TBL] [Abstract][Full Text] [Related]
27. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
[TBL] [Abstract][Full Text] [Related]
28. Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor.
Rossi F; Liu M; Tieniber A; Etherington MS; Hanna A; Vitiello GA; Param NJ; Do K; Wang L; Antonescu CR; Zeng S; Zhang JQ; DeMatteo RP
Clin Cancer Res; 2023 Jun; 29(11):2144-2157. PubMed ID: 36971786
[TBL] [Abstract][Full Text] [Related]
29. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
Qi C; Pan F; Li J; Li Y; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
[TBL] [Abstract][Full Text] [Related]
31. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
33. Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA.
Teuber A; Schulz T; Fletcher BS; Gontla R; Mühlenberg T; Zischinsky ML; Niggenaber J; Weisner J; Kleinbölting SB; Lategahn J; Sievers S; Müller MP; Bauer S; Rauh D
Nat Commun; 2024 Jan; 15(1):63. PubMed ID: 38167404
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.
Zhang P; Wang M; Li J; Gao X; Zhang B; Liang H; Zhou Y; Liao G; Feng F; Zhou Y; Yu J; Zhang J; Zhou Y; Ye Y; Chen J; Zhao Q; Shen K; Cao H; Tao K
Adv Ther; 2022 Jun; 39(6):2920-2931. PubMed ID: 35462602
[TBL] [Abstract][Full Text] [Related]
35. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Heinrich MC; Griffith D; McKinley A; Patterson J; Presnell A; Ramachandran A; Debiec-Rychter M
Clin Cancer Res; 2012 Aug; 18(16):4375-84. PubMed ID: 22745105
[TBL] [Abstract][Full Text] [Related]
36. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Dewaele B; Wasag B; Cools J; Sciot R; Prenen H; Vandenberghe P; Wozniak A; Schöffski P; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2008 Sep; 14(18):5749-58. PubMed ID: 18794084
[TBL] [Abstract][Full Text] [Related]
37. [Advanced GIST: Which treatments in 2022?].
Mas L; Bachet JB
Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
Senchak J; Ahr K; von Mehren M
Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
[TBL] [Abstract][Full Text] [Related]
39. New treatments in advanced gastrointestinal stromal tumor.
Serrano C
Curr Opin Oncol; 2021 Jul; 33(4):323-328. PubMed ID: 33867479
[TBL] [Abstract][Full Text] [Related]
40. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
Fan J; Yang M; Huang B; Wang Z; Luo D; Zhang J; Zhang P; Shi H; Li Y; Nie X
Diagn Pathol; 2020 Jan; 15(1):8. PubMed ID: 32005261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
